Skip to main content
. 2021 Mar 23;12(10):1549–1557. doi: 10.1111/1759-7714.13939

FIGURE 4.

FIGURE 4

Targeted binding of miRNA‐218‐5p and protein kinase, DNA‐activated, catalytic polypeptide (PRKDC). (a) StarBase predictions were used to identify the binding and mutated sites of miRNA‐218‐5p and PRKDC. (b) Expression of PRKDC in lung carcinoma in TCGA database. (c) Reverse transcription quantitative polymerase chain reaction (RT‐qPCR) was used to evaluate the relative expression of PRKDC in the serum of patients with lung carcinoma. (d) Pearson's test was applied to identify any correlation involving miRNA‐218‐5p and PRKDC in patients with lung carcinoma. (e) Dual‐luciferase reporter gene analysis of miRNA‐218‐5p and PRKDC target binding. (f) and (g) RT‐qPCR and WB were used to evaluate PRKDC mRNA and protein levels, respectively, in radiation‐resistant lung carcinoma cells transfected with miRNA‐218‐5p‐mimic/inhibitor. *p < 0.05; ***p < 0.001